Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study
Background: Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with unresectable non-small cell lung cancer (NSCLC). Cisplatin-etoposide (EP) and weekly carboplatin-paclitaxel (PC) are commonly used concurrent regimens, but comparative data on efficacy and toxicity remain limited. This study com...